

## [Dasatinib](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.2. Targeted therapies](#)

ATC codes: [L01EA02](#)

EMLc

Indication

Chronic myeloid leukaemia, not elsewhere classified ICD11 code: [2C03.2](#)

INN

Dasatinib

Medicine type

Chemical agent

List type

Complementary

Additional notes

Imatinib-resistant chronic myeloid leukaemia

Formulations

**Oral > Solid:** 20 mg tablet ; 50 mg tablet ; 70 mg tablet ; 80 mg tablet ; 100 mg tablet (EML) ; 140 mg tablet (EML)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Dasatinib](#)

DrugBank

[Dasatinib](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of dasatinib 100 mg and 140 mg tablets from the EMLc.